ArriVent BioPharma, Inc.

AVBP · Nasdaq · SIC 2834: Pharmaceutical Preparations
40
SEC Filings

Business Summary

PARTI Overview We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize our teams deep drug development experience to maximize the potential of our lead product candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, including ARR-217 (MRG007), through approval and ...

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAVBPdiscussed_in_filing Cybersecurity
topic_mentionAVBPdiscussed_in_filing Trusted Computing
topic_mentionAVBPdiscussed_in_filing Blockchain & Crypto
topic_mentionAVBPdiscussed_in_filing Regulation
topic_mentionAVBPdiscussed_in_filing Healthcare & Bio
topic_mentionAVBPdiscussed_in_filing Platform & Ecosystem
topic_mentionAVBPdiscussed_in_filing Cybersecurity
topic_mentionAVBPdiscussed_in_filing Trusted Computing
topic_mentionAVBPdiscussed_in_filing Blockchain & Crypto
topic_mentionAVBPdiscussed_in_filing Regulation
topic_mentionAVBPdiscussed_in_filing Healthcare & Bio
topic_mentionAVBPdiscussed_in_filing Platform & Ecosystem
topic_mentionAVBPdiscussed_in_filing Cybersecurity
topic_mentionAVBPdiscussed_in_filing Trusted Computing
topic_mentionAVBPdiscussed_in_filing Blockchain & Crypto
topic_mentionAVBPdiscussed_in_filing Regulation
topic_mentionAVBPdiscussed_in_filing Healthcare & Bio
topic_mentionAVBPdiscussed_in_filing Platform & Ecosystem
topic_mentionAVBPdiscussed_in_filing Cybersecurity
topic_mentionAVBPdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-052025-12-310001104659-26-024127EDGAR116K words
2025-03-032024-12-310001558370-25-001999EDGAR—
2024-03-282023-12-310001558370-24-004280EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001104659-25-108847EDGAR20K words
2025-08-112025-06-300001558370-25-010975EDGAR—
2025-05-122025-03-310001558370-25-007276EDGAR—
2024-11-142024-09-300001558370-24-015624EDGAR—
2024-08-142024-06-300001558370-24-012236EDGAR—
2024-05-082024-03-310001558370-24-007197EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-170001104659-26-029588EDGAR1K words
2026-03-050001104659-26-024112EDGAR—
2025-11-100001104659-25-108839EDGAR—
2025-09-090001558370-25-011954EDGAR—
2025-08-110001558370-25-010974EDGAR—
2025-07-210001104659-25-069169EDGAR—
2025-07-020001104659-25-065386EDGAR—
2025-06-230001104659-25-061375EDGAR—
2025-06-200001104659-25-061165EDGAR—
2025-05-120001558370-25-007259EDGAR—

40 total filings indexed. 21 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001868279
TickerAVBP
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d496d781cb1a770b0160cee0fe465522ade65b25fba95ca0169746143b921fc5
parent: 490bfe0af2985c548ead1a59a70b52400f2d3fc0b1a4ff6c3e076b1ca0e5d8db
content hash: d924c3ef19dc786dba0776c36fab8b628894de9d8fe5c2873d90cdba8cfe54be
signed: 2026-04-13T04:43:48.951Z
sources: 9 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf